Testosterone-suppression therapy does not help early-stage prostate cancer, warns Grace L. Lu-Yao, PhD, MPH. The treatment, called primary androgen deprivation therapy (ADT), does not extend these patients’ lives, and it has significant side effects, including impotence, diabetes and bone loss. Primary ADT is appropriate only for men with very aggressive prostate cancer as shown by a PSA greater than 50 or a PSA score that doubles in less than 12 months.
The post Testosterone-Suppression Therapy Does Not Help Early-Stage Prostate Cancer appeared first on Bottom Line Personal.